Vancouver
Originally published online as doi:10.1189/jlb.0409255 on October 30, 2009

Published online before print October 30, 2009
This Article
Free via Open Access: OA
Right arrow OA Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Supplemental Movies and Legends
Right arrowOA All Versions of this Article:
jlb.0409255v1
87/2/203    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Loynes, C. A.
Right arrow Articles by Renshaw, S. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loynes, C. A.
Right arrow Articles by Renshaw, S. A.
Related Collections
Right arrowRelated Article
(Journal of Leukocyte Biology. 2010;87:203-212.)
© 2010 The Author(s)

Pivotal Advance: Pharmacological manipulation of inflammation resolution during spontaneously resolving tissue neutrophilia in the zebrafish

Catherine A. Loynes*,{dagger}, Jane S. Martin*,{dagger}, Anne Robertson*,{dagger}, Daniel M. I. Trushell*,{dagger}, Philip W. Ingham*,{ddagger}, Moira K. B. Whyte*,{dagger} and Stephen A. Renshaw*,{dagger},1

* MRC Centre for Developmental and Biomedical Genetics,
{dagger} Department of Infection and Immunity, University of Sheffield, Western Bank, Sheffield, United Kingdom; and
{ddagger} Institute of Molecular and Cell Biology, Singapore

1. Correspondence: MRC Centre for Developmental and Biomedical Genetics, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK. E-mail: s.a.renshaw{at}sheffield.ac.uk

ABSTRACT

Zebrafish are a unique model for pharmacological manipulation of physiological processes such as inflammation; they are small and permeable to many small molecular compounds, and being transparent, they permit the visualization and quantitation of the inflammatory response by observation of transgenically labeled inflammatory cell populations. Using a transgenic line specifically labeling neutrophils in vivo (mpx:GFP), we studied the effects of a range of pharmacological agents on the resolution of inflammation in vivo. These agents were selected for their ability to modulate neutrophil function and lifespan in human neutrophils in vitro. Agents delaying neutrophil apoptosis (LPS, dbcAMP, and several caspase inhibitors) all lead to a delay in resolution of neutrophilic inflammation. Reciprocally, pyocyanin and roscovitine (inducers of neutrophil apoptosis) lead to reduced neutrophil numbers. The occurrence of apoptosis was observed by time-lapse analysis and confirmed by dual staining for neutrophil-specific mpx activity (TSA staining) and an apoptotic marker (TUNEL). During inflammation, macrophages follow neutrophils into the inflamed site, and TUNEL/TSA dual-positive material can be demonstrated within macrophages, consistent with their uptake of apoptotic neutrophils. This model has several advantages over mammalian models and lends itself to the study of pharmaceutical agents modulating inflammation.

Key Words: apoptosis • granulocytes • neutrophils • compound screen


Related Article

Editorial: Maintaining the balance—fishing for drugs to treat persistent neutrophilic inflammation
Chris Hall and Phil Crosier
J. Leukoc. Biol. 2010 87: 189-191. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
C. Hall and P. Crosier
Editorial: Maintaining the balance--fishing for drugs to treat persistent neutrophilic inflammation
J. Leukoc. Biol., February 1, 2010; 87(2): 189 - 191.
[Full Text] [PDF]